Table 1 Features of the included studies
No | Author | Year | NCT | cancers | durgs | Pts | follow-up (months) | Effecacy | Safety |
|---|---|---|---|---|---|---|---|---|---|
1 | Rodabe N. Amaria | 2018 | NCT02519322 | Melanoma | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 23 | 15.0 vs 15.6 | ORR, pCR, surgery rate, OS, PFS, RFS | 3–4 grade AEs |
2 | Boris Sepesia | 2022 | NCT03158129 | NSCLC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 44 | NA | surgery rate, R0 rate | all-cause mortality |
3 | Tina Casconea | 2021 | NCT03158129 | NSCLC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 44 | average 22.2 | ORR, MPR, pCR, OS, RFS | 3–4 grade AEs, completed therapy |
4 | Jonathan D Schoenfeldb | 2020 | NCT02919683 | OSCC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 29 | average 14.2 | ORR, MPR, pCR, OS, PFS | 3–4 grade AEs, completed therapy |
5 | Jonathan D Schoenfeldb | 2022 | NCT02919683 | OSCC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 29 | NA | NA | updated completed therapy, all-cause mortality |
6 | Renata Ferrarotto | 2020 | NCT03144778 | OPSCC | Anti-PD-L1 VS. Anti-PD-L1 + Anti-CTLA-4 | 28 | average 15.79 | ORR, MPR, pCR | 3–4 grade AEs |
7 | Ahmed Omar Kaseb | 2022 | NCT03222076 | HC | Anti-PD-1 VS. Anti-PD-1 + Anti-CTLA-4 | 27 | NA | ORR, pCR, PFS, surgery rate | 3–4 grade AEs, all-cause mortality |
8 | A. Leary | 2021 | NCT03249142 | OC | Anti-PD-L1 VS. Anti-PD-L1 + Anti-CTLA-4 | 66 | NA | MPR, surgery rate, R0 rate | 3–4 grade AEs, completed therapy |
9 | Hye Ryun Kim | 2021 | NCT03737968 | HNSCC | Anti-PD-L1 VS. Anti-PD-L1 + Anti-CTLA-4 | 36 | average 4.3 | ORR | NA |
10 | Hyun-Sung Lee | 2023 | NCT02592551 | MPM | Anti-PD-L1 VS. Anti-PD-L1 + Anti-CTLA-4 | 20 | average 34.1 | MPR、AEs | NA |